Phaseline

Companies › Sapience Therapeutics

Sapience Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ST101–Phase 1GlioblastomaDec 2026
ST316
WNT/β-catenin signaling pathway inhibitor
–Phase 1Colon CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04478279ST101Phase 1GlioblastomaOncologyDec 2026
NCT05848739ST316Phase 1Colon CancerOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.